Other Events ·
Liquidia Corporation announced that the U.S. Food and Drug Administration granted Fast Track Designation to YUTREPIA…
LQDALiquidia Corp
Liquidia Corporation announced that the U.S. Food and Drug Administration granted Fast Track Designation to YUTREPIA (treprostinil) inhalation powder for treating Raynaud's phenomenon associated with systemic sclerosis (SSc-RP). This designation facilitates expedited development and review due to the serious nature of the condition and lack of approved therapies, potentially enabling rolling New Drug Application review. The company plans to initiate the RE-WARM Phase 2a dose-finding study in October 2026 for approximately 75 adults with SSc-RP. Liquidia Corporation is a biopharmaceutical company focused on developing and commercializing products for respiratory and vascular diseases using its proprietary PRINT technology.